Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Preferred Stock Liabilities: 2021

Historic Preferred Stock Liabilities for Amylyx Pharmaceuticals (AMLX) over the last 1 years, with Dec 2021 value amounting to $239.4 million.

  • Amylyx Pharmaceuticals' Preferred Stock Liabilities was N/A to $239.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was $239.4 million, marking a year-over-year change of. This contributed to the annual value of $239.4 million for FY2021, which is N/A change from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Preferred Stock Liabilities of $239.4 million as of FY2021.
  • Amylyx Pharmaceuticals' Preferred Stock Liabilities' 5-year high stood at $239.4 million during FY2021, with a 5-year trough of $239.4 million in FY2021.
  • For the 1-year period, Amylyx Pharmaceuticals' Preferred Stock Liabilities averaged around $239.4 million, with its median value being $239.4 million (2021).